Hypertension (Dallas, Tex. : 1979) · 2025
Effects of Blood Pressure Control on Arterial Stiffness Mechanisms in SPRINT: A Randomized Controlled Trial.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pewowaruk Ryan, Jaeger Byron C, Hughes Timothy M, Upadhya Bharathi, Kitzman Dalane W, Supiano Mark A, Gepner Adam D
Аннотация
BACKGROUND: The longitudinal impact of blood pressure (BP) control on the components of arterial stiffness has not been studied.
METHODS: The SPRINT (Systolic BP Intervention Trial) compared an intensive systolic BP goal (<120 mm Hg) to a standard goal (<140 mm Hg). Carotid-femoral pulse wave velocity (PWV) was measured in a subset of participants (n=605) at 0, 1, 2, and 3 years after randomization. Structural stiffening due to remodeling of the vessel wall and load-dependent stiffening, from changes in BP, were calculated by adjusting PWV to a 120/80 mm Hg reference BP with participant-specific models. The effect of intensive BP control on BP and arterial stiffness components over time was evaluated using generalized least squares regression.
RESULTS: Intensive BP control slowed the progression of PWV (total stiffness) compared with standard BP control at 3-year follow-up (-0.49 [-0.02 to -0.96] m/s, P=0.042). Differences in total stiffness between treatment groups over 3 years of follow-up were driven by intensive BP control reducing load-dependent PWV (-0.71 [-0.58 to -0.85] m/s, P<0.001), not structural PWV (+0.20 [-0.26 to +0.66], P=0.40). Load-dependent PWV was lower in the intensive treatment group at 1 year and remained lower throughout the follow-up. In contrast, structural PWV was similar between the 2 groups and increased throughout the follow-up period.
CONCLUSIONS: Intensive BP control slowed the progression of total arterial stiffness by decreasing load-dependent stiffness, but not through reduced structural stiffness. Future investigations are needed to determine if load-dependent PWV may have potential utility as a biomarker to monitor the efficacy of treatment and guide BP management strategies.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01206062.
METHODS: The SPRINT (Systolic BP Intervention Trial) compared an intensive systolic BP goal (<120 mm Hg) to a standard goal (<140 mm Hg). Carotid-femoral pulse wave velocity (PWV) was measured in a subset of participants (n=605) at 0, 1, 2, and 3 years after randomization. Structural stiffening due to remodeling of the vessel wall and load-dependent stiffening, from changes in BP, were calculated by adjusting PWV to a 120/80 mm Hg reference BP with participant-specific models. The effect of intensive BP control on BP and arterial stiffness components over time was evaluated using generalized least squares regression.
RESULTS: Intensive BP control slowed the progression of PWV (total stiffness) compared with standard BP control at 3-year follow-up (-0.49 [-0.02 to -0.96] m/s, P=0.042). Differences in total stiffness between treatment groups over 3 years of follow-up were driven by intensive BP control reducing load-dependent PWV (-0.71 [-0.58 to -0.85] m/s, P<0.001), not structural PWV (+0.20 [-0.26 to +0.66], P=0.40). Load-dependent PWV was lower in the intensive treatment group at 1 year and remained lower throughout the follow-up. In contrast, structural PWV was similar between the 2 groups and increased throughout the follow-up period.
CONCLUSIONS: Intensive BP control slowed the progression of total arterial stiffness by decreasing load-dependent stiffness, but not through reduced structural stiffness. Future investigations are needed to determine if load-dependent PWV may have potential utility as a biomarker to monitor the efficacy of treatment and guide BP management strategies.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01206062.